Home MarketIpca Laboratories Ltd.

Ipca Laboratories Ltd. Stock Info: As on 2017-10-18 14:44:44

Nse

492.00

-3.55(-0.72%)
Change%
52 Week Range
400.00
11.00
657.60
5.00
Open499.75
Day's Range396.44 - 594.66
Value Traded (in ₹ Cr.) 2.61

Bse

493.00

-2.85(-0.57%)
Change %
52 Week Range
400.00
11.00
656.00
5.00
Open497.50
Day's Range396.68 - 595.02
Value Traded (in ₹ Cr.) 0.43

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 58,216,236.00 46.13%
Mutual Funds/UTI 29,612,700.00 23.47%
FII 16,670,124.00 13.21%
Employee 0.00 0.00%
Public 13,588,130.00 10.77%
Government 0.00 0.00%
Others 5,414,850.00 4.29%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 2.60
Basic EPS (Rs.) 7.25
Cash EPS 20.69
BVPerShare Excl 182.73
Operating Revenue 223.13
PBDITPerShare 24.40
Dividend 0.00
NPPerShare 7.25
Current Ratio 1.82
Quick Ratio 0.82
PriceToBV 3.17
Earnings 0.01
PBDIT Margin 10.93
PBT Margin 3.85
NP Margin 3.24
Return On Assets 2.39
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,838.92
Total Expenses 2,730.40
EBITDA 307.91
PBT 108.52
PAT 91.45
Net Income 91.45
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,322.34
Total Expenses 1,239.92
EBITDA -1.55
PBT 61.49
PAT 60.87
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 25.24
Net worth 2,306.09
Investments 96.47
Total Liability 3,822.84
Total debt 595.01
Net block 2,097.02
Total Assets 3,822.84
Parameter Sep-16 (₹ Cr.) 6M % change
Total share capital 25.24
Net worth 2,247.78
Investments 142.42
Total Liability 3,862.28
Total debt 854.70
Net block 2,080.22
Total Assets 3,862.28
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533 527.35 1.07
521.05539.95

Abbott India Ltd.

4167.2 4229.05 -1.46
4120.054319.8

Ajanta Pharma Ltd.

1193.3 1198.35 -0.42
1146.91216.1

Albert David Ltd.

280 281.85 -0.66
279287.95

Alembic Ltd.

38.4 38.6 -0.52
38.440.75

Alembic Pharmaceuticals Ltd.

501 500.3 0.14
490.1506

Alkem Laboratories Ltd.

1828 1824.8 0.18
18101874
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

71.4 76.15 -6.24
75.0590.95

Aarti Drugs Ltd.

533.15 526.9 1.19
524.35539.05

Aayush Food & Herbs Ltd.

44.7 44.95 -0.56
40.546.4

Abbott India Ltd.

4165 4225.25 -1.43
4149.74320

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 485.09
Cash from investing activities -202.90
Cash from financing activities -213.96
Net change in cash 68.23

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.97%
ICICI Prudential Long Term Equity Fund 3.17%
DSP BlackRock Micro-Cap Fund 2.10%
DSP BlackRock Small And Mid Cap Fund 2.19%
Franklin India Smaller Companies Fund 1.52%
Mirae Asset Emerging Bluechip Fund 1.77%

LIC Housing withdraws NCLT plea against DB Realty

LIC Housing Finance has settled loan dispute with DB Realty and also withdrawn its application before the National Company Law Tribunal to start insolvency process against the builder for recovery of Rs 31 crore debt. In a filing with the BSE, DB Realty informed that the company and LIC Housing Finance have arrived at a settlement and have executed a debt settlement agreement. Pursuant thereto, LIC has on October 16 withdrawn an application made by it in the National Company Law Tribunal (NCLT) Mumbai against DB Realty and the said application by LIC therefor stands disposed off as withdrawn, the filing said. DB Realty said that there are no bankruptcy proceedings pending against the company. LIC Housing Finance had filed an application before the NCLT to start insolvency process against DB Realty for recovery of Rs 30.63 crore outstanding loan. Earlier, DB Realty had said the company availed of Rs 200 crore loan from LIC Housing Finance Ltd in January 2010 and out of that, Rs 188 crore were disbursed to it. The developer had repaid Rs 157.37 crore to LIC Housing Finance within 18 months from the disbursement and the balance loan outstanding remained at Rs 30.63 crore. In the Delhi-NCR property market, insolvency proceedings have started in Jaypee Infratech and Amrapali group company. The real estate sector is facing a multi-year demand slowdown, resulting in huge delays in delivery of flats, forcing buyers to go on protest at sites and file legal cases in courts. Many developers have defaulted in repayment of their bank loans.

17-10-2017 15:50

Infosys to announce Q2 results on Oct 24

The country’s second largest software services firm Infosys will announce its financial results for the second quarter on October 24. “Infosys will announce the results for its second quarter ended September 30, 2017 on Tuesday, October 24, 2017 around 3:45 pm Indian Standard Time,” Infosys said in a BSE filing today. Against from its usual practice, Infosys has delayed the announcement of results by a couple of days — it typically announces its financial numbers at the beginning of the earnings season. Moreover, the company has opted to release results after the trading hours, against the usual practice of making a morning announcement. Its larger rival, Tata Consultancy Services, had announced its second quarter earnings last week, while others are slated to do so in the coming days. The Bengaluru-based firm had been in the eye of a storm over the past few months, with founders and erstwhile board members fighting over allegations of lapses in corporate governance and irregularities in Infosys’ $200-million Panaya acquisition. The spat — often public — culminated in the sudden resignation of the then CEO Vishal Sikka and exit of four board members, including ex-Chairman R Seshasayee. They blamed founder N R Narayana Murthy’s “misguided campaign” for the abrupt exit of Sikka. Infosys, on August 24, then named co-founder Nandan Nilekani as its new Non-Executive Chairman, bowing to the demands of co-founders and large institutional investors. Nilekani, at the time of taking over had promised that bringing stability to Infosys would be on the top of his priority list. He had also stated that he would review the strategy and present the company's future blueprint in October.

17-10-2017 14:24

Firstsource Solutions allots 94,375 equity shares

Firstsource Solutions said that it has allotted 94,375 equity shares under Employee Stock Option Scheme 2003 of the Company. “The Company has allotted 94,375 Equity shares of Rs.10/- each bearing distinctive numbers 682,240,988 to 682,335,362 on 13th October 2017, under Employee Stock Option Scheme 2003 of the Company,” the company said in a filing to the Bombay Stock Exchange. Consequent to the said allotment, the paid up capital of the Company has increased to Rs. 6,823,353,620 consisting of 682,335,362 Equity shares of Rs.10/- each. Meanwhile, shares of the company were trading at Rs 41.20 apiece, down 0.84 per cent from the previous close at 13:30 hour son BSE.

17-10-2017 13:26

MAS Financial to debut on bourses tomorrow

Non-banking financial company MAS Financial Services will make stock market debut tomorrow after having concluded its initial share sale offer last week. The Rs 460-crore initial public offer (IPO) was over- subscribed 128 times from October 6-10. The company had fixed the price band at Rs 456-459 per share for the IPO. MAS Financial is a Gujarat-headquartered NBFC with more than two decades of business operations. Net proceeds from the fresh issue will be utilised towards augmenting its capital base to meet future requirements. Motilal Oswal Investment Advisors managed the company's IPO. The shares are proposed to be listed on National Stock Exchange and BSE.

17-10-2017 12:53

Maruti’s new Dzire crosses 1 lakh sales mark in over 5 months

Maruti Suzuki’s all-new Dzire has achieved the fastest 1-lakh sales mark, a distinctive feat in the Indian automobile industry. The third generation Dzire, launched in May 2017, has surpassed the 1-lakh sales milestone in just five and half months. Positioned as an authentic sedan offering plush and roomy interiors, loaded with new features and equipped with advanced safety features, the new Dzire became an instant hit. Dzire has won the prestigious Good Design Awards 2017, hosted by the Japan Institute of Design Promotion in Japan. The new Dzire takes the brand to a whole new level – an authentic sedan designed for the young, aspirational and indulgence seeking Indian customer, MSI Senior Executive Director (Marketing and Sales) R S Kalsi said. Built afresh on the HEARTECT platform, the new Dzire continues to fulfil the growing aspirations of young and prosperous India, he added. MSI said its Auto Gear Shift (AGS) technology has found increasing acceptance among customers with 17 per cent of Dzire customers opting for AGS variant during April-September 2017. The model is also equipped with features like SmartPlay infotainment system with Android Auto, Apple CarPlay and Mirror-link technology. Fuel efficiency is also one of the main attractions of the new Dzire with the diesel variant delivering 28.4 kmpl while petrol variant giving 22 kmpl, the company said. Meanwhile, shares of the company were trading at Rs 7857.50 apiece, up 0.13 per cent from the previous close at 12:50 hours on BSE.

17-10-2017 12:44

Ipca Laboratorie - Compliance Certificate For The Period Ended September 30, 2017

Pursuant to the Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility are maintained during the period April 1, 2017 to September 30, 2017 (both days inclusive) by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number : INR000004058.

17-Oct-2017 03:15 PM

Ipca Laboratorie - Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And

Pursuant to Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a certified copy of the compliance certificate for the period ended September 30, 2017 under Regulation 40(9) issued by M/s. Parikh Parekh & Associates, practicing Company Secretaries.

17-Oct-2017 03:03 PM

Ipca Laboratorie - Shareholding for the Period Ended September 30, 2017

Ipca Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017.

12-Oct-2017 01:20 PM

Ipca Laboratorie - Statement Of Investor Complaints For The Quarter Ended 30Th September, 2017.

statement of investor complaints for the quarter ended 30th September, 2017.

12-Oct-2017 01:13 PM

Ipca Laboratorie - Updates

We refer to NSE's letter dt. 11.09.2017 and wish to inform that the Company has no information / announcement (including impending announcement) to make on its operations /performance or any other price sensitive information which in our opinion has a bearing on the price / volume behaviour of the Company's scrip.

12-Sep-2017 11:00 AM

Ipca Laboratorie - Compliance Certificate For The Period Ended September 30, 2017

Pursuant to the Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility are maintained during the period April 1, 2017 to September 30, 2017 (both days inclusive) by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number : INR000004058.

17-Oct-2017 03:15 PM

Ipca Laboratorie - Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And

Pursuant to Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a certified copy of the compliance certificate for the period ended September 30, 2017 under Regulation 40(9) issued by M/s. Parikh Parekh & Associates, practicing Company Secretaries.

17-Oct-2017 03:03 PM

Ipca Laboratorie - Shareholding for the Period Ended September 30, 2017

Ipca Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017.

12-Oct-2017 01:20 PM

Corporate Details

About Management

One of the first modern pharma factory of yesteryears was commissioned by Ipca at Mumbai in 1969. The company was originally promoted by a group of medical professionals and businessmen and was incorporated as 'The Indian Pharmaceutical Combine Association Limited.' in October 1949. The present management took over in November 1975 when the total turnover of the company was just Rs. 0.54 crores. Currently, this premise where Ipca started its operations, houses the Registered Office of the company. Key departments like International Marketing, R&D (Formulations) and Analytical Development Lab are located here. YEAR EVENTS 1949 - Ipca Laboratories Ltd. was incorporated on 19th October, in Mumbai, under the name `The Indian Pharmaceutical Combine Association Limited'. The Company manufacture pharmaceutical products such as tablets, capsules, vials and ampoules. The Company was promoted by a group of medical professionals viz., Dr. N.K. Chaina, Dr. A.M. Desai, Dr. N.S. Tibrawala, K.M. Shroff, S.F. Kirawal, U.H. Dalal and K.B. Mehla. 1964 - The name was subsequently changed to `Ipca Laboratories Ltd.' on 6th August 1964. The name was further changed to `Ipca Laboratories Private Limited' on 13th January 1966. The name of the company was again changed to `Ipca Laboratories Ltd.' on 9th August 1988. The company became a Public Limited Company on 24th March, 1993. 1975 - The management of the company was taken over by Amitabh Bachchan, Ajitabh Bachchan, Jaya Bachchan, M.R. Chandurkar, P.C. Godha. 1994 - The Company undertook to set up a modern plant at Athal, Silvassa, for manufacture of pharmaceutical formulations. Plant and machinery comprising blenders, auto tablet coaters, fluid bed dryers, etc., procured indigenously. The Tatlam bulk drug unit capacity was increased to 500 TPA. 1995 - 9,225,000 No. of equity shares allotted to promoters, friends, relatives and associates (of these, 225,000 were Rights shares at a premium of Rs 120 per share). During February, the Company issued 3,275,000 No. of equity shares of Rs 10 each at a premium of Rs 120 per share of which 150,000 shares reserved for allotment on a preferential basis to employees of the Company (all were taken up). Balance 3,125,000 shares issued to the public (all were taken up). 2002-R S Hugar, former managing director of Global Trust Bank, has joined the board of directors of Ipca as non-executive chairman with effect from June 11, 2002. 2003 -Launched new domestic marketing division, ACTIVA , dedicated to Rheumatology Care. First Company in India to have such division for marketing superspeciality molecules. - Launched new domestic marketing division,Hy Care dedicated to Cardio-Diabetology segments. - Wholly owned subsidiary `Ipca Pharmaceuticals Inc.' incorporated in United States of America. -Wholly owned subsidiary `Ipca Laboratories (UK) Ltd.' incorporated in United Kingdom. - Forbes, a leading US business magazine, selected among its top 200 successful, rising companies outside USA, with sales under USD 1 Billion. 2004 -Members of the Company have approved the amalgamation in the nature of merger of Innotech Pharma Ltd., a 100% subsidiary of the Company, with Company -Ipca Laboratories Ltd. unveils novel injectable antibiotic combination of cefotaxime sodium with sulbactam sodium for the first time in the country under the brand name 'Sultax' -Received 'Lifetime Achievement Award' for the year2002-03 from from CHEMEXIL (Basic Chemicals,Pharmaceuticals & Cosmetics Export Promotion Council)for export promotion over the years. -Commissioned new formulation plant at Silvassa -Forbes Asia, a leading US business magazine selected Ipca, for the second consecutive year as one among the first 200 'Best under a Billion Company' in Asia 2005 -Ipca Laboratories Ltd has informed that the Company has entered into a Joint Venture (JV) agreement with Chongqing Holley Holding Company Ltd of China. -Merger of Innotech Pharma Limited with Ipca Laboratories Limited in August, 2005. -Acquires Cardiac brand ISORDIL from Wyeth Limited. -Forbes Asia, a leading US business magazine selected Ipca, for the third consecutive year as one among the first 200 'Best under a Billion Company' in Asia. - Ipca Laboratories has given the Bonus in the Ratio of 1:1 2006 -Ipca Laboratories Enters into Strategic Alliance with Ranbaxy Pharmaceuticals Inc., for the US Market -Ipca Laboratories launches fixed dose ACT combination and stops manufacturing of single ingredient Oral Artemisinin derivatives. -Ipca's new plant at Dehradun commenced operation on 5th May, 2006 2007 -Ipca - Ranbaxy Alliance received U.S. FDA marketing approval for Atenolol Tablets -Ipca Laboratories granted US FDA approval for Hydroxychloroquine sulfate tablet -Ipca Laboratories - Acquisition of 100% shareholding of formulation dossier registration holding companies in Australia and N -Ipca launched eighth domestic marketing division, 'Altus' which caters to intensivists and surgeons. -Ipca has been awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2007. In the past, company has received same award for three consecutive years' 2003, 2004 and 2005. 2008 -Ipca Laboratories receives US FDA approval for Propranolol Hydrochloride Tablets -Tonira Pharma's Nandesari unit (API plant at Baroda) receives US-FDA approval. -Ipca Laboratories Ltd has re-appointed Mr. Premchand Godha as the Managing Director of the Company for a further period of 5 years w.e.f. April 01, 2008. -Ipca-Piparia, formulation manufacturing unit receives MHRA-UK approval. This is the 3rd plant after Athal and Kandla receiving this qualification. -WHO prequalify Ipca's dossier of ARTESUNATE + AMODIAQUINE Co Blister making Ipca the 2nd company in the world and the first Indian company to receive this prequalification. 2009 -Ipca received Best Patent Award during the year 2007 - 08 2010 - Ipca Laboratories Ltd has informed that the Board of Directors of the Company at its meeting held on January 21, 2010, inter alia, appointed Mr. Anand T Kusre as a Director of the Company. -Company has splits its Face value of Shares from Rs 10 to Rs 2 2011 -Ipca Laboratories has received approval from UK Medicines and Healthcare Products Regulatory Agency for its fourth manufacturing unit at a Special Economic Zone in Indore for good manufacturing practices under the regulator. -Ipca labs bags nod to amalgamate Tonira Pharma 2012 -Mr. Dev Parkash Yadava has been appointed as an Additional Director of the Company -IPCA Laboratories bags USFDA nod Indore formulations manufacturing facility 2013 -IPCA received Corporate Citizen Award' for best corporate governance practice. -IPCA Dehradun won the "Energy Conservation" Award for the 3rd year in a row. -IPCA featured on the 8th position in the list of 'India's Most Admired Companies, in a survey carried out by Fortune India, in collaboration with The Hay Group, for the second time. -IPCA Laboratories said that SEZ Indore formulations manufacturing unit has been found acceptable after the inspection of US-FDA. 2014 -IPCA Laboratories "Acquisition of High Potency Oral Solid Dosage formulations manufacturing unit situated at Pithampur near Indore". -IPCA has entered into an alliance with Oncobiologics, Inc. USA for the development, manufacture and commercialization of biosimilar monoclonal antibody products. -IPCA Sports Club wins the E-Merck Inter-Pharma Cricket Tournament. -IPCA acquires formulations manufacturing unit located at Tarapur, Dist. Palghar, Maharashtra. -IPCA Sports Club wins Dreamz Trophy (T-20 & 40-overs format). -New product Launch - Pacimolr Active -Whistle Blower Policy implemented. 2016 -Ipca Lab wins Clinical and Research Excellence (CARE) awards. -Ipca was awarded by 'Indian Drug Manufacturers Association (IDMA) Best Formulation Patent (2014-15)' for its formulation patent of Hydroxychloroquine and its combinations in treatment of Diabetes Mellitus at 54th IDMA annual day celebration held on 23rd January 2016. -Ipca Laboratories wins the 'Clinical Trial result of the year' at the first annual CARE Award held at Boston, USA on 27th April 2016. -Ipca's Ratlam manufacturing Unit won 1st prize in National Energy Conservation Award 2016. This ceremony was hosted in Delhi on 14th December 2016. -Ipca Laboratories has been conferred with "Intellectual Property (IP) Excellence Award 2016" for adopting "The Best Practices in IP Intelligence" in a function organized in Mumbai on November 28th, 2016.

Registered Office

Village Ranu, (Taluka Padra),

2662-227300,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.